Defiance ETFs’s AbbVie ABBV Stock Holding History

Defiance ETFs’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.88M	Buy	7,506 +1,544	+26%	+$332K	0.03%	214
2026 Q1	$1.3M	Buy	+5,962	New	+$1.32M	0.02%	192

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Defiance ETFs's ABBV Position: Q2 2026 in Review

Defiance ETFs increased its AbbVie (ABBV) stake by 26% in Q2 2026, buying an estimated $332K and bringing the position to 7,506 shares worth $1.88M. The position accounts for 0.03% of the portfolio, ranked #214.

Defiance ETFs first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Defiance ETFs held 7,506 shares of AbbVie worth $1.88M as of Q2 2026.
Defiance ETFs bought 1,544 AbbVie shares in Q2 2026, an estimated $332K.
AbbVie made up 0.03% of Defiance ETFs's portfolio in Q2 2026, its #214 holding.
Defiance ETFs first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Defiance ETFs's 13F filing for Q2 2026, filed 14 Aug 2026.